Compare Inovio Pharmaceuticals Inc (INO) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.72 (market cap $5.86B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 52.2× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and State Street SPDR Bloomberg High Yield Bond ETF for 61 Days on average.
| INO | JNK | |
|---|---|---|
Market Cap | $112.19M | $5.86B |
Volume | 3,201,278 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $2.65 | $98.02 |
52-Week Low | $0.66 | $92.30 |
Typical Hold Time | 43 Days | 61 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
JNK (SPDR Bloomberg High Yield Bond ETF) trades at $92.81 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments of $0.53 per share. Recent news highlights institutional interest with Envestnet Asset Management increasing its stake by 23.3% during the latest quarter.
The outlook for JNK is challenged by rising bond yields and macroeconomic uncertainty. While consistent dividends provide income appeal, the bearish technical setup and high-yield bond sensitivity to interest rate hikes present near-term risks. Institutional accumulation suggests long-term confidence, but investors should monitor credit market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
